The US Food and Drug Administration has given an accelerated approval for a new treatment for metastatic melanoma that combines two licenced GlaxoSmithKline Plc medicines which block signalling in different sites of the same molecular pathway. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
